# A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

> **NCT05405725** · PHASE3 · COMPLETED · sponsor: **Enzene Biosciences Ltd.** · enrollment: 504 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **BIOLOGICAL:** ENZ215
- **BIOLOGICAL:** Prolia

## Key facts

- **NCT ID:** NCT05405725
- **Lead sponsor:** Enzene Biosciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-04
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 504 (ACTUAL)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405725, "A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05405725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*